Kalcipos-D forte 500mg/800 IU chewable tablets *

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 15 June 2021

File name

ie-spc-se0805-chew-v034-clean_1623777890.pdf

Reasons for updating

  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 15 June 2021

File name

ie-pl-se0805-chew-v034-clean_1623777864.pdf

Reasons for updating

  • Change to section 5 - how to store or dispose
  • Change to section 6 - date of revision

Updated on 20 October 2020

File name

ie-spc-se0805-chew-v031g-clean_1603198163.pdf

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 20 October 2020

File name

ie-pl-se0805-chew-v031g-clean_1603197972.pdf

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - excipient warnings
  • Change to section 4 - how to report a side effect
  • Change to section 6 - what the product contains
  • Change to section 6 - date of revision

Updated on 13 August 2019

File name

ie-pl-se0805-chewable-clean-mahtransfer_1541611750.pdf

Reasons for updating

  • Change to product name

Updated on 08 November 2018

File name

ie-pl-se0805-chewable-clean-mahtransfer_1541611750.pdf

Reasons for updating

  • New PIL for new product

Updated on 07 November 2018

File name

ie-spc-se0805-chewable-mahtransfer-clean_1541611802.pdf

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 16 July 2018

File name

Kalcipos_Chewable_Tablets_SmPC_July_2018.docx

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 2: Indication – adults over 18 years

In section 4.3: Severe renal impairment added, Hypercalciuria and hypercalcaemia and diseases and/or conditions resulting in which lead to hypercalcaemia or hypercalciuria added

In section 4.4: Information regarding milk-alkali syndrome added

In section 4.6: Information regarding pregnancy added

In section 4.8: Full adverse reaction definitions added

In section 5.1: Information regarding pharmacotherapeutic group added

In section 5.2: Information regarding absorption, distribution added

In section 10: Date of revision changed.

 

Updated on 11 January 2016

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 2: there is a slight text change

In section 4,2: Restructuring to this section has been undertaken

In section 4.3: Reference to use in children has been removed from this section

In section 4.5: Information regarding calcium salts has been added. Information regarding orlistat has been added.

In section 4.7: Warning in relation to driving and use of machinery has been added

In section 4.8: Information regarding patients with renal impairment has been added

In In section 10: The date of revision has been changed.

Updated on 11 January 2016

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 11 January 2016

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 2: there is a slight text change

In section 4,2: Restructuring to this section has been undertaken

In section 4.3: Reference to use in children has been removed from this section

In section 4.5: Information regarding calcium salts has been added. Information regarding orlistat has been added.

In section 4.7: Warning in relation to driving and use of machinery has been added

In section 4.8: Information regarding patients with renal impairment has been added

In In section 10: The date of revision has been changed.

Updated on 01 December 2015

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.4 - Special precautions for storage
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 3: A slight amendment has been made to the description of the pharmaceutical form

In section 4.4: Very minor typo correct

In section 4.8: adverse reaction reporting statement has been added

In section 5.2: slight correction made to two sub-headings

In section 6.4: Reference to in-use has been added

In section 9: date of last renewal has been added

In section 10: The date of revision has been changed.

Updated on 01 December 2015

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.4 - Special precautions for storage
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 3: A slight amendment has been made to the description of the pharmaceutical form

In section 4.4: Very minor typo correct

In section 4.8: adverse reaction reporting statement has been added

In section 5.2: slight correction made to two sub-headings

In section 6.4: Reference to in-use has been added

In section 9: date of last renewal has been added

In section 10: The date of revision has been changed.

Updated on 10 October 2013

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 5.1: Additional information has been added to this section outlining the results of a clinical study

In section 10: The date of revision has been changed.

Updated on 10 October 2013

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 5.1: Additional information has been added to this section outlining the results of a clinical study

In section 10: The date of revision has been changed.

Updated on 27 November 2012

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.4; A correction has been made regarding the content of sucrose

Updated on 27 November 2012

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Free text change information supplied by the pharmaceutical company

In section 4.4; A correction has been made regarding the content of sucrose

Updated on 13 November 2012

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.1 - List of excipients

Free text change information supplied by the pharmaceutical company

In section 4.4: a correction has been made to the sucrose content. it was incorrectly stated to be 3.8mg and this has now been corrected to 1.8mg
In section 6.1: the list of excipients has been amended

Updated on 13 November 2012

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.1 - List of excipients

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.4: a correction has been made to the sucrose content. it was incorrectly stated to be 3.8mg and this has now been corrected to 1.8mg
In section 6.1: the list of excipients has been amended

Updated on 07 November 2012

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 2: text regarding the excipients has been changed

In section 3: additional information regarding the descriptions of the tablet has changed

In section 4.3: text has changed regarding the contraindications

In section 4.5: Additional warning regarding the administration of strontium and calcium has been added.

In section 4.6: additional information regarding fertility has been added

In section 4.8: small correction made to the frequencies

In section 6.3: additional information regarding the in-shelf life use has been added

In section 6.5; the word chewable has been added

In section 10: the revision date has changed

Updated on 07 November 2012

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 2: text regarding the excipients has been changed

In section 3: additional information regarding the descriptions of the tablet has changed

In section 4.3: text has changed regarding the contraindications

In section 4.5: Additional warning regarding the administration of strontium and calcium has been added.

In section 4.6: additional information regarding fertility has been added

In section 4.8: small correction made to the frequencies

In section 6.3: additional information regarding the in-shelf life use has been added

In section 6.5; the word chewable has been added

In section 10: the revision date has changed

Updated on 21 September 2012

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 2: information regarding the excipients has been removed

In section 4.3: Information regarding hydrogenated soya oil has been removed

In section 4.4: a correction has been made to the quantitative composition of sucrose

In section 6.1: the excipient list has changed

In section 10: the revision date has changed

Updated on 21 September 2012

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 2: information regarding the excipients has been removed

In section 4.3: Information regarding hydrogenated soya oil has been removed

In section 4.4: a correction has been made to the quantitative composition of sucrose

In section 6.1: the excipient list has changed

In section 10: the revision date has changed

Updated on 29 February 2012

Reasons for updating

  • New SPC for medicines.ie

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 29 February 2012

Reasons for updating

  • New SPC for medicines.ie

Free text change information supplied by the pharmaceutical company

None provided